Designs for Health®, the practitioner-recommended and preferred brand for high-quality, research-backed supplements, today ...
Survival outcomes with curative intent hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal metastasis. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not ...
Neoadjuvant penpulimab combined with taxanes and carboplatin in triple-negative breast cancer: A single-arm, open-label, multi-center phase II clinical study (neoTAPPL). This is an ASCO Meeting ...
Adding camrelizumab to neoadjuvant chemotherapy increases pathological complete response rate to 56.8% vs 44.7% with placebo in early or locally advanced triple-negative breast cancer. The combination ...
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed ...
TipRanks on MSN
Akeso, Inc. Begins Promising Phase III Study on AK112 for Triple-Negative Breast Cancer
Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. has launched a Phase III clinical study titled ‘A ...
A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease ...
A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback